|
|
|
|
|
|
|
|
|
|
SUMMARY:
For more than 25 years CA125 has been the main biomarker for the management of women with EOC. Recently, novel biomarkers have become available clinically that improve upon the use of CA125 for the risk assessment and management of women with ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.